Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company developing novel multispecific immuno-oncology therapeutics, today announced a new solid tumor strategy designed to fight cancer on multiple fronts. The Company has filed a patent application covering a proprietary Nectin-4 x PD-L1 dual-targeting backbone designed to strengthen Aptevo's oncology pipeline, expand partnering opportunities and support multiple therapeutic approaches from a single platform-derived innovation.

For Aptevo, the filing helps secure the engine behind that strategy. Instead of pursuing one product built for one use, the filing will protect a backbone that may be adapted into multiple cancer-fighting approaches. That gives Aptevo more ways to advance its own pipeline, expands opportunities to work with large pharmaceutical companies and brings new thinking to the challenges of treating solid tumors.